Nektar Therapeutics (NASDAQ: NKTR) revenue
Nektar Therapeutics reported revenue of $55.2m for fiscal 2025, 43.9% less than in fiscal 2024 ($98.4m). Since fiscal 2016 its revenue has fallen by 66.6%, an average decline of 11.5% a year.
Nektar Therapeutics's best year of the last 10 was fiscal 2018. The biggest drop was in fiscal 2019, −90.4%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $55.2m | −43.9% | −$140.1m | −253.7% |
| 2024 | $98.4m | +9.2% | −$105.2m | −106.9% |
| 2023 | $90.1m | −2.1% | −$263.7m | −292.6% |
| 2022 | $92.1m | −9.7% | −$376.2m | −408.6% |
| 2021 | $101.9m | −33.4% | −$446.1m | −437.8% |
| 2020 | $152.9m | +33.4% | −$425.1m | −278.0% |
| 2019 | $114.6m | −90.4% | −$440.0m | −383.9% |
| 2018 | $1,193m | +287.8% | $687.9m | 57.6% |
| 2017 | $307.7m | +86.0% | −$59.6m | −19.4% |
| 2016 | $165.4m | — | −$112.9m | −68.2% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Nektar Therapeutics revenue compared with its sector
By revenue for its latest fiscal year, Nektar Therapeutics ranks 323rd of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Nektar Therapeutics, −43.9%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 321st | CVRX | $56.7m | 10.4% |
| 322nd | 908 Devices | $56.2m | 17.7% |
| 323rd | Nektar Therapeutics | $55.2m | −43.9% |
| 324th | Agios Pharmaceuticals | $54.0m | 48.0% |
| 325th | Invivyd | $53.4m | 110.5% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Nektar Therapeutics
- How much revenue did Nektar Therapeutics make in fiscal 2025?
- Nektar Therapeutics reported revenue of $55.2m for fiscal 2025, compared with $98.4m in fiscal 2024.
- How much has the revenue of Nektar Therapeutics fallen?
- Between fiscal 2016 and fiscal 2025 it went from $165.4m to $55.2m: 66.6% less, an average decline of 11.5% a year.
- What was the best year for revenue at Nektar Therapeutics?
- Of its last 10 fiscal years, fiscal 2018, with $1,193m.
- Where does Nektar Therapeutics rank in its sector by revenue?
- It ranks 323rd of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Nektar Therapeutics come from?
- From the annual report (Form 10-K) that Nektar Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Nektar Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Nektar Therapeutics: the Nektar Therapeutics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.